Literature DB >> 17561842

Ferroportin1 and hephaestin are involved in the nigral iron accumulation of 6-OHDA-lesioned rats.

Jun Wang1, Hong Jiang, Jun-Xia Xie.   

Abstract

Elevated iron levels in the substantia nigra (SN) participate in neuronal death in Parkinson's disease (PD). While the mechanisms underlying the increased iron are still unknown, some iron transport proteins may be involved. The nigral iron accumulation could be a result of either increased import or decreased export. The mechanisms of iron import have received considerable attention, but little is known about iron export mechanisms. Ferroportin1 (FP1) and hephaestin (HP), two newly discovered iron export proteins, cooperate in the iron export in the gut. Here, we investigated their expression in the SN of rats lesioned by 6-hydroxydopamine (6-OHDA). Using immunofluorescence, we showed that FP1 and HP were both expressed on astrocytes, microglia, oligodendrocytes and neurons in the SN. By immunohistochemistry, we showed that 1 day after 6-OHDA lesion, the expression of the two proteins decreased compared with the control. When rats began showing rotation behaviour induced by apomorphine, usually 6 weeks after 6-OHDA lesion, they are considered PD models. In these PD models, a further decrease in the two proteins was observed. Reverse transcriptase-polymerase chain reaction showed that the mRNA levels of FP1 and HP decreased 1 day after 6-OHDA lesion compared with the control, and further decrease was also observed in the PD model rats. These results show for the first time that FP1 and HP co-localize in the rat brain, and suggest that decreased expression of these transporters in the SN can account for the increased iron levels.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17561842     DOI: 10.1111/j.1460-9568.2007.05515.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  27 in total

1.  Dose- and time-dependent alpha-synuclein aggregation induced by ferric iron in SK-N-SH cells.

Authors:  Wen-Jing Li; Hong Jiang; Ning Song; Jun-Xia Xie
Journal:  Neurosci Bull       Date:  2010-06       Impact factor: 5.203

2.  Oxidative stress partially contributes to iron-induced α-synuclein aggregation in SK-N-SH cells.

Authors:  Wenjing Li; Hong Jiang; Ning Song; Junxia Xie
Journal:  Neurotox Res       Date:  2010-04-10       Impact factor: 3.911

Review 3.  Potential neuroprotective activity of Ginseng in Parkinson's disease: a review.

Authors:  Elena González-Burgos; Carlos Fernandez-Moriano; M Pilar Gómez-Serranillos
Journal:  J Neuroimmune Pharmacol       Date:  2014-10-29       Impact factor: 4.147

4.  The Ferroxidase Hephaestin But Not Amyloid Precursor Protein is Required for Ferroportin-Supported Iron Efflux in Primary Hippocampal Neurons.

Authors:  Changyi Ji; Brittany L Steimle; Danielle K Bailey; Daniel J Kosman
Journal:  Cell Mol Neurobiol       Date:  2017-11-25       Impact factor: 5.046

Review 5.  Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis.

Authors:  David Devos; Z Ioav Cabantchik; Caroline Moreau; Véronique Danel; Laura Mahoney-Sanchez; Hind Bouchaoui; Flore Gouel; Anne-Sophie Rolland; James A Duce; Jean-Christophe Devedjian
Journal:  J Neural Transm (Vienna)       Date:  2020-01-07       Impact factor: 3.575

6.  Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration.

Authors:  David T Dexter; Sarah A Statton; Charlotte Whitmore; Wolfhardt Freinbichler; Peter Weinberger; Keith F Tipton; Laura Della Corte; Roberta J Ward; Robert R Crichton
Journal:  J Neural Transm (Vienna)       Date:  2010-12-17       Impact factor: 3.575

Review 7.  Iron transport across the blood-brain barrier: development, neurovascular regulation and cerebral amyloid angiopathy.

Authors:  Ryan C McCarthy; Daniel J Kosman
Journal:  Cell Mol Life Sci       Date:  2014-10-30       Impact factor: 9.261

8.  Overdosing on iron: Elevated iron and degenerative brain disorders.

Authors:  Santosh R D'Mello; Mark C Kindy
Journal:  Exp Biol Med (Maywood)       Date:  2020-09-02

Review 9.  Brain iron homeostasis: from molecular mechanisms to clinical significance and therapeutic opportunities.

Authors:  Neena Singh; Swati Haldar; Ajai K Tripathi; Katharine Horback; Joseph Wong; Deepak Sharma; Amber Beserra; Srinivas Suda; Charumathi Anbalagan; Som Dev; Chinmay K Mukhopadhyay; Ajay Singh
Journal:  Antioxid Redox Signal       Date:  2013-08-15       Impact factor: 8.401

Review 10.  Brain Iron Metabolism Dysfunction in Parkinson's Disease.

Authors:  Hong Jiang; Jun Wang; Jack Rogers; Junxia Xie
Journal:  Mol Neurobiol       Date:  2016-04-02       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.